IBD: Exploring TL1A and the Next Frontier

This activity is supported by an educational grant from Merck & Co., Inc.


1.25CME
1.25AAPA
75MINS
H727_HEA001_OG_1200x630

Overview


Provider Statement

This continuing education activity is provided by Vindico Medical Education


Support Statement

This activity is supported by an educational grant from Merck & Co., Inc.


Activity Description

Clinical outcomes for patients with inflammatory bowel disease (IBD) have improved significantly over the past decade with the introduction of biologic therapies targeting key cytokines and receptors involved in the pathophysiology of IBD. However, further advancements are needed, as roughly 1 in 3 patients do not respond to agents such as tumor necrosis factor (TNF) inhibitors, anti-interleukin-12/23 therapies, or anti-integrins. Emerging treatment options, including those targeting the TNF-like cytokine 1A (TL1A) pathway, have demonstrated promising efficacy in clinical trials for reducing both intestinal inflammation and fibrosis. In this engaging and discussion-based CE program, experts in the field discuss the limitations within the current IBD treatment landscape, review the role of the TL1A pathway in IBD pathogenesis, report the latest clinical evidence on emerging TL1A therapies, and discuss their potential impact on IBD management strategies.


Target Audience

The intended audience for this activity is physicians and advanced practice providers specializing in gastroenterology who are involved in the management of patients with inflammatory bowel disease (IBD).


Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Recognize the limitations of current IBD treatments and the need for new options.
  • Examine the role of the TL1A pathway in IBD pathogenesis and implications for disease management.
  • Assess the latest clinical evidence on emerging TL1A therapies to identify patients with IBD who may benefit.
  • Discuss the potential impact of emerging TL1A therapies on IBD management strategies.

Activity Chair

Bruce E. Sands, MD, MS, AGAF, FACG
Chief, Dr. Henry D. Janowitz Division of Gastroenterology
Dr. Burrill B. Crohn Professor of Medicine
Icahn School of Medicine at Mount Sinai
Mount Sinai Health System
New York, NY


Faculty

Maia Kayal, MD, MS
Associate Professor
The Susan and Leonard Feinstein IBD Center
Dr. Henry D. Janowitz Division of Gastroenterology
Icahn School of Medicine at Mount Sinai
New York, NY

Millie D. Long, MD, MPH, AGAF, FACG
Division Chief, Division of Gastroenterology and Hepatology
Professor of Medicine
University of North Carolina at Chapel Hill
Chapel Hill, NC

Dr. Dermot P.B. McGovern, MBBS, D.Phil, FRCP, AGAF, FACG
Joshua L. and Lisa Z. Greer Chair of IBD Genetics
Director, Precision Health
F. Widjaja Inflammatory Bowel Disease Institute
Cedars-Sinai Medical Center
Los Angeles, CA

Planners/Reviewers

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Linda A. Giarraputo, BS, PA-C


Accreditation

ACCME Jointly accredited In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

aapaVindico Medical Education has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1.25 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until November 19, 2027. PAs should only claim credit commensurate with the extent of their participation.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.

This enduring material is approved for 1 year from the date of original release, November 20, 2026, to November 19, 2027.


How to Participate in This Activity and Obtain CE Credit

To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 of the 4 posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate or AAPA Category 1 CME certificate.

In addition to providing a downloadable certificate, CME Providers accredited by the Accreditation Council for Continuing Medical Education (ACCME) have the ability to transmit CME credit data for all US physicians to an online repository, the ACCME Program and Activity Reporting System (PARS). CME credit data submitted to PARS can be viewed, managed, and tracked by US physicians in "CME Passport," a free, centralized web application. US Physicians who opt-in by providing their medical license number, state of licensure, and date of birth will have their credits automatically reported to the ACCME.


Disclosures

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible companies. All relevant financial relationships with ineligible companies have been mitigated prior to the commencement of the activity.

Relationship information is accurate at the time of content development.

Activity Chair and Faculty report the following relevant financial relationship(s)

Maia Kayal, MD, MS
Consultant: AbbVie, Abivax, Celltrion, Johnson & Johnson, Lilly, OSE Immunotherapeutics, Takeda
Independent Research Contractor: Pfizer

Millie D. Long, MD, MPH, AGAF, FACG
Consultant: AbbVie, Abivax, BMS, Celltrion, Intercept, Johnson & Johnson, Lilly, Merck, Pfizer, Sanofi, Spyre, Takeda

Dr. Dermot P.B. McGovern, MBBS, D.Phil, FRCP, AGAF, FACG
Royalties or Patent Beneficiary: Merck
Speaker Contracted by Ineligible Company: Merck
*Individual Stocks (privately held): Mirador Therapeutics

Bruce E. Sands, MD, MS, AGAF, FACG
Consultant: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Celltrion, Genentech/Roche, Gilead, GSK, J&J Innovative Medicine, Lilly, Merck, Pfizer, Sanofi, Takeda, Teva
Speaker Contracted by Ineligible Company: AbbVie, Celltrion, Genentech/Roche, J&J Innovative Medicine, Merck, Mitsubishi Tanabe, Pfizer, Takeda
Stock Options: Caldera, Mirador, SRT Therapeutics

Planners/Reviewers report the following relevant financial relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Linda A. Giarraputo, BS, PA-C
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relevant financial relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.


Unlabeled and Investigational Usage

The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.


AI Usage Disclosure Statement

Vindico Medical Education may use artificial intelligence (AI) tools to support the planning, development, review, evaluation, or administration of accredited continuing education activities. Any AI-assisted content or process is subject to human oversight, validation, and approval to ensure that the education remains accurate, evidence-based, balanced, independent, and free of commercial bias. When AI is used in a manner that materially affects learner-facing content or learner interaction, Vindico discloses that use and remains responsible for the integrity and quality of the accredited education.


Accessibility

Vindico Medical Education is committed to providing an inclusive learning environment and ensuring equitable access to our educational content. Our educational activities may include accessibility features, such as captioning, transcripts, reading aloud, and other platform-supported tools, to assist learners.

Participants who require additional accommodation, alternative formats, or assistance accessing content are encouraged to contact us at CME@VindicoCME.com. Vindico will make all reasonable efforts to provide alternative formats in a timely manner.


Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2026 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.


Procedures for Reporting Copyright Infringement

If you suspect that any content in this activity violates your copyright, you can request the removal of such content or restrict access to it by contacting our designated copyright agent (as outlined below). In your email, kindly provide the following details:

  • Specify the copyrighted work you believe has been infringed upon.
  • Describe the work and, if possible, include the location (eg, URL) of an authorized version of the work.
  • Share your name, address, telephone number, and, if available, your email address.
  • Assert that you genuinely believe that the use of the materials in question is not authorized by the copyright owner, its agent, or the law.
  • Confirm that the information you have provided is accurate and send an attestation, "under penalty of perjury," that you are either the copyright owner or have the authority to act on behalf of the copyright owner.
  • Provide a signature or its electronic equivalent from the copyright holder or a representative authorized to act on their behalf.

Our agent for copyright issues relating to this web activity is as follows:
Vindico Medical Education, LLC
Attn: Faith Bantivoglio
6900 Grove Road, Building 300
Thorofare, NJ 08086
fbantivoglio@vindicocme.com
or call: 856-994-9400, ext. 614


CE Questions?

Contact us at cme@vindicoCME.com